8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Spray-drying stands as one of the most used techniques to produce inhalable microparticles, but several parameters from both the process and the used materials affect the properties of the resulting microparticles. In this work, we describe the production of drug-loaded chondroitin sulphate microparticles by spray-drying, testing the effect of using different solvents during the process. Full characterisation of the polymer and of the aerodynamic properties of the obtained microparticles are provided envisaging an application in inhalable tuberculosis therapy. The spray-dried microparticles successfully associated two first-line antitubercular drugs (isoniazid and rifabutin) with satisfactory production yield (up to 85%) and drug association efficiency (60%–95%). Ethanol and HCl were tested as co-solvents to aid the solubilisation of rifabutin and microparticles produced with the former generally revealed the best features, presenting a better ability to sustainably release rifabutin. Moreover, these presented aerodynamic properties compatible with deep lung deposition, with an aerodynamic diameter around 4 μm and fine particle fraction of approximately 44%. Finally, it was further demonstrated that the antitubercular activity of the drugs remained unchanged after encapsulation independently of the used solvent.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          Deposition of particles in the human respiratory tract in the size range 0.005–15 μm

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pulmonary surfactant in health and human lung diseases: state of the art.

            M Griese (1999)
            Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant prevents alveolar collapse at low lung volume, and preserves bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant. A pathophysiological role for surfactant was first appreciated in premature infants with respiratory distress syndrome and hyaline membrane disease, a condition which is nowadays routinely treated with exogenous surfactant replacement. Biochemical surfactant abnormalities of varying degrees have been described in obstructive lung diseases (asthma, bronchiolitis, chronic obstructive pulmonary disease, and following lung transplantation), infectious and suppurative lung diseases (cystic fibrosis, pneumonia, and human immunodeficiency virus), adult respiratory distress syndrome, pulmonary oedema, other diseases specific to infants (chronic lung disease of prematurity, and surfactant protein-B deficiency), interstitial lung diseases (sarcoidosis, idiopathic pulmonary fibrosis, and hypersensitivity pneumonitis), pulmonary alveolar proteinosis, following cardiopulmonary bypass, and in smokers. For some pulmonary conditions surfactant replacement therapy is on the horizon, but for the majority much more needs to be learnt about the pathophysiological role the observed surfactant abnormalities may have.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting dendritic cells with biomaterials: developing the next generation of vaccines.

              Current vaccine and immunotherapy technology faces ongoing challenges in both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the world. A possible key to developing the next generation of vaccines is the ability to deliver antigen to dendritic cells (DCs) more specifically and induce the subsequent activation of T-cell immunity. However, antigen delivery to, and activation of, DCs is a complex problem, involving antigen transport to DC-rich areas, DC binding and antigen uptake, and antigen processing and presentation. Addressing these challenges requires novel and multidisciplinary approaches, for example, the application of biomaterials to immunotechnology. Here, we review the latest advances in biomaterial drug vehicles, such as polymer microparticles and nanoparticles, and liposomes, that are being used to target DCs in new strategies for vaccination.
                Bookmark

                Author and article information

                Journal
                Polymers (Basel)
                Polymers (Basel)
                polymers
                Polymers
                MDPI
                2073-4360
                12 February 2020
                February 2020
                : 12
                : 2
                : 425
                Affiliations
                [1 ]Centre for Marine Sciences, Faculdade de Ciências e Tecnologia, Universidade do Algarve, 8005-139 Faro, Portugal; susananasus@ 123456gmail.com (S.R.); noelia.florez@ 123456uvigo.es (N.F.-F.)
                [2 ]Centre for Biomedical Research, Universidade do Algarve, 8005-139 Faro, Portugal; mfaleiro@ 123456ualg.pt
                [3 ]Algarve Chemistry Research Centre and Department of Chemistry and Pharmacy, Universidade do Algarve, 8005-139 Faro, Portugal; amcosta@ 123456ualg.pt
                [4 ]Faculdade de Ciências e Tecnologia, Universidade do Algarve, 8005-139 Faro, Portugal
                [5 ]Department of Chemical Engineering, University of Vigo, Faculty of Sciences, As Lagoas, 32004 Ourense, Spain; matorres@ 123456uvigo.es
                [6 ]Food and Drug Department, University of Parma, 43124 Parma, Italy; francesca.buttini@ 123456unipr.it
                Author notes
                [* ]Correspondence: amgrenha@ 123456ualg.pt ; Tel.: +351-289-244-441
                Author information
                https://orcid.org/0000-0002-0329-4265
                https://orcid.org/0000-0003-0225-9537
                https://orcid.org/0000-0002-2666-2315
                https://orcid.org/0000-0002-4472-4823
                https://orcid.org/0000-0002-2136-1396
                Article
                polymers-12-00425
                10.3390/polym12020425
                7077709
                32059360
                6149b26b-283e-46f0-a54f-182cb3be3430
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 30 January 2020
                : 11 February 2020
                Categories
                Article

                chondroitin sulphate,isoniazid,inhalable microparticles,rifabutin,solvents,spray-drying

                Comments

                Comment on this article